Press release
Pharmaceuticals and medical technology will go hand in hand in future – DESITIN and cerbomed sign distribution agreement
The successful medium-sized independent company DESITIN has been a specialist provider and proficient partner to doctors and patients in the treatment of epilepsy for many years. By taking on the distribution of the cerbomed NEMOS therapeutic device, DESITIN is now also extending its expertise in the epilepsy treatment market to the medical technology sector.
“It is important to approach epilepsy treatment in a holistic way – this ranges from suitable lifestyle choices to the use of anticonvulsants right through to neurostimulation procedures, providing a useful addition to drug therapy. Due to its non-invasiveness, transcutaneous vagus nerve stimulation is especially suitable for this approach and we can now offer it to specialists in addition to our existing medications,” said Dr. Martin Zentgraf, General Manager of DESITIN Arzneimittel GmbH.
“We are looking forward to working with DESITIN, one of the strongest partners in the epilepsy treatment sector. This partnership offers doctors competent advice and gives patients access to a comprehensive range of treatment,” said Dr. Andreas Hartlep, Chief Executive Officer of cerbomed GmbH.
Both companies will be present at the 88th Congress of the German Society for Neurology, from September 23rd until 26th, 2015, in Düsseldorf, Germany.
About t-VNS with NEMOS
Transcutaneous Vagus Nerve Stimulation is addressed to patients suffering from various difficult-to-treat neurological and psychiatric diseases. The t-VNS therapy uses the fact that a branch of the vagus nerve is located directly under the skin in areas of the outer ear and therefore can be stimulated through the skin (transcutaneously) with electrical impulses.
With NEMOS cerbomed developed and patented a special stimulator and a dedicated ear electrode for treatment of epilepsies with t-VNS. The stimulator, which is connected with the ear electrode, sends out the electrical impulses. With the transcutaneous vagus nerve stimulator NEMOS a targeted stimulation of the vagus nerve is possible without the need of a surgery.
About DESITIN Arzneimittel GmbH
DESITIN is a german independent medium-sized specialist pharmaceutical company with approximately 290 employees, predominantly located at the company site in Hamburg.
DESITIN is also financially independent and finances its developments and investments from its own sales. As a complete pharmaceutical company, DESITIN manufactures the majority of its products in-house.
Besides being a contractual partner of hospitals and service providers DESITIN is committed to two innovative supply models for improving disease progression in epileptic patients.
Besides its main, domestic market in Germany, DESITIN’s anti-epileptics also help patients in Scandinavia and Eastern Europe.
For further information visit www.desitinpharma.com.
About cerbomed
Cerbomed GmbH is an innovative medical device company located in Erlangen, Germany, that focuses on neuromodulation. The company, founded in 2005, focuses on transcutaneous Vagus Nerve Stimulation (t-VNS), which may offer an attractive therapy option for patients with hard-to-treat neurological and psychiatric illnesses.
The transcutaneous Vagus Nerve Stimulation received the European clearance (CE mark) for the treatment of epilepsies, depression and pain. Two clinical studies regarding the effectiveness of t-VNS in patients with drug-resistant epilepsy and chronic migraine have been finished in 2014.
The therapy device NEMOS for treatment of epilepsies is available in Germany and 11 further countries of the EU.
Please visit us on www.cerbomed.com.
Dr. Martin Hyca, Director Marketing & Sales
Henkestrasse 91, DE-91052 Erlangen
+49 9131 9202 76 30
martin.hyca@cerbomed.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pharmaceuticals and medical technology will go hand in hand in future – DESITIN and cerbomed sign distribution agreement here
News-ID: 316454 • Views: …
More Releases from cerbomed GmbH
transcutaneous Vagus Nerve Stimulation for epilepsies now available in Norway
ERLANGEN/DRAMMEN, May 28th, 2015 – To address the Norwegian market with transcutaneous Vagus Nerve Stimulation (t-VNS), the medical device company cerbomed from Erlangen, Germany, is cooperating with an experienced distribution partner: Scan-Med A/S from Drammen, Norway.
The company, founded in 1982, considers itself as a connecting link between manufacturers of medical devices and hospitals, as well as health institutions and specialized on distribution service and support of medical equipment.
“We are…
Vagus nerve stimulation without surgery now available in Denmark, Finland and Sw …
ERLANGEN/AALBORG, Mai 28th, 2015 – More than 30 percent of all epilepsy patients still suffer from continued occurrence of seizures, despite appropriate treatment with anticonvulsive drugs. For these patients, only few treatment alternatives are available at the moment. One promising therapy option is transcutaneous Vagus Nerve Stimulation (t-VNS), now also available for patients in Denmark, Sweden and Finland. This has been made possible by cerbomed‘s new distributor Cephalon A/S.…
Trial results for transcutaneous Vagus Nerve Stimulation in pharmacoresistant ep …
ERLANGEN/DRESDEN, 30th April 2015 – At the 9th annual joint conference of the three German-speaking regions of the International League Against Epilepsy in Dresden, the results of a trial on transcutaneous Vagus Nerve Stimulation (t-VNS) in pharmacoresistant epilepsy were presented for the first time.
Trial shows reduction in seizures with t-VNS
In the multi-centre, randomised, controlled, 2-arm, double-blind study, 76 adult epilepsy patients from Germany and Austria were treated over 5…
More Releases for DESITIN
Baby Powder Market Technology, Recent Trends, Demand, Future Growth, Product, Sh …
This Baby Powder market report is segmented into several unique and crucial industry segments and applications to offer a precise market overview. Industries will learn about the immense prospects accessible in the market via this thorough Market research study in this Baby Powder market report. Global Baby Powder size is estimated to be xx million in 2021 from USD 292.8 million in 2020, with a change of XX% between 2020…
Global Adult Diaper Rash Cream Market Trends, Size, Competitive Analysis and For …
The global adult diaper rash cream market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The rising incidence of urinary incontinence among adults which demand the use of adult diapers majorly leads to diaper rashes among adults. Thus, to address this condition, the market has gained substantial traction. Further, the market growth is also driven by factors including the rising incidences of skin infections among…
Sodium Valproate Market 2020| Worldwide Industry Share, Size, Gross Margin, Tren …
In-depth Report On Sodium Valproate Market including Market Landscape, and Market size, Revenues by players, Revenues by regions.
The global Sodium Valproate market is broadly analyzed in this report that sheds light on critical aspects such as the vendor landscape, competitive strategies, market dynamics, and regional analysis. The report helps readers to clearly understand the current and future status of the global Sodium Valproate market. The research study comes out as…
Parkinson's Disease Drug Market to Witness Huge Growth by 2026| Key Players are …
The Global Parkinson's Disease Drug Market Report 2020 is a professional and in-depth study on the current state of the Parkinson's Disease Drug Market.
This report focuses on Parkinson's Disease Drug volume and value at global level, regional level and company level. From a global perspective, this report represents overall Parkinson's Disease Drug market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North…
Sodium Valproate Market Huge Growth Opportunity By 2024 | Top Vendors Sanofi-ave …
Valproate (VPA), and its valproic acid, sodium valproate, and valproate semisodium forms, are medications primarily used to treat epilepsy and bipolar disorder and to prevent migraine headaches. It is useful for the prevention of seizures in those with absence seizures, partial seizures, and generalized seizures.
Sodium Valproate Market research report covers key players, trends, status, future forecast, size-share, development trends, challenges, opportunities. It provides insight into the growth of value players,…
Sodium Valproate Market: Top Key Players Sanofi-aventis, AbbVie, Athenex, Fresen …
Sodium Valproate Market research report 2018-2023 presents a comprehensive study of the Sodium Valproate Market in Global Industry; the study scans the progression of the market trailed over the past few years and the forecasts of growth in the coming years, primarily in terms of sales. The research report highlights the reasons liable for the disparities in the market and investigates them methodically. The Sodium Valproate Market effect factors have…
